- Argentina beats Dutch in shootout to reach World Cup final
- Tanard Jackson suspended indefinitely by NFL — again
- FAA investigating fireworks drone flights
- Pentagon: We’ll give Obama a drone strike with al-Baghdadi’s name on it
- Marine in Mexican custody to get day in court after 101 days
- Senate OKs San Antonio mayor as housing secretary
- NFL star likely fooled by Marine impostor who accepted first-class plane ticket
- Sen. Ted Cruz tweets Obama directions from fundraisers to border towns
- Israel hits key Hamas targets in Gaza offensive
- Ten-year sentence for New Orleans’ Nagin on graft charges
It's yet another example of his lack of transparency
Topic - Diana Zuckerman
Hip replacements are slightly more likely to fail in women than in men, according to one of the largest studies of its kind in U.S. patients. The risk of the implants failing is low, but women were 29 percent more likely than men to need a repeat surgery within the first three years.
"They imply that the FDA approval decision isn't that important in deciding how this test will be used," said Diana Zuckerman, president of the Cancer Prevention and Treatment Fund. "By claiming to pass the buck to the experts in the field, FDA is not taking responsibility for the agency's influential decision to approve the test as a replacement of the Pap smear for women over 25."
"Unfortunately the HPV test by itself isn't very useful because so many young women have HPV that will disappear without any treatment," said Diana Zuckerman of the Cancer Prevention and Treatment Fund. "Having an HPV test without also getting a Pap smear to check for problems is going to scare a lot of women who are not developing cervical cancer."